Page last updated: 2024-12-06

glutaurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glutaurine: recently deteccted hormone of parathyroid gland; structure; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glutaurine : A dipeptide resulting from the formal condensation of the amino group of taurine with the gamma-carboxy group of L-glutamic acid. It was initially found in the parathyroid in 1980 and later in the brain of mammals. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68759
CHEMBL ID2106758
CHEBI ID27694
SCHEMBL ID1533805
MeSH IDM0075184

Synonyms (33)

Synonym
litoralon
glutaurina [inn-spanish]
gamma-l-glutamyltaurine
l-glutamine, n-(2-sulfoethyl)-
glutaurina [spanish]
glutaurinum [inn-latin]
glutaurine [inn]
brn 5342709
n-(2-sulfoethyl)-l-glutamine
gamma-glutamyltaurine
56488-60-9
5-l-glutamyl-taurine
C05844
glutaurine
5-glutamyl-taurine
unii-b5t2z06y9n
b5t2z06y9n ,
glutaurinum
glutaurina
CHEMBL2106758
AKOS016008803
gamma-l-glutamyl-taurine
WGXUDTHMEITUBO-YFKPBYRVSA-N
SCHEMBL1533805
DTXSID20205030
(2s)-2-amino-4-[(2-sulfoethyl)carbamoyl]butanoic acid
gamma-gt
(s)-2-amino-5-oxo-5-((2-sulfoethyl)amino)pentanoic acid
CHEBI:27694
Q5572470
AMY23344
HY-106608
CS-0026146

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Oral treatment with glutaurine in a dose of 1-20 micrograms was ineffective on electroshock-induced amnesia if the treatment was applied before the electroconvulsive shock."( Effects of glutaurine treatment on electroshock-induced amnesia. Antiamnesic action of glutaurine.
Balázs, M; Telegdy, G,
)
0.84

Dosage Studied

ExcerptRelevanceReference
" Their respective dose-response curves had a similar maximum but the slope of the curve for AMPA was consistently steeper than that for quisqualate."( The pharmacology of quisqualate and AMPA in the cerebral cortex of the rat in vitro.
Horne, AL; Simmonds, MA, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
mammalian metaboliteAny animal metabolite produced during a metabolic reaction in mammals.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
anticonvulsantA drug used to prevent seizures or reduce their severity.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
hormoneOriginally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds.
anticonvulsantA drug used to prevent seizures or reduce their severity.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
hormoneOriginally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
L-glutamine derivativeA proteinogenic amino acid derivative resulting from reaction of L-glutamine at the amino group, the carboxy group, or the carboxamide, or from the replacement of any hydrogen of L-glutamine by a heteroatom.
sulfonic acid
dipeptide zwitterionAny peptide zwitterion comprising two amino acid residues. Major structure at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Taurine and Hypotaurine Metabolism59

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (82.69)18.7374
1990's7 (13.46)18.2507
2000's2 (3.85)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.17 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index3.99 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (98.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]